Status:
UNKNOWN
FOUND - Ancillary Study to Smile Protocol NCT03654105
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborating Sponsors:
University of Parma
University of Milan
Conditions:
COVID 19
Inflammatory Status
Eligibility:
All Genders
50-75 years
Brief Summary
During the current pandemic, in Italy the majority of asymptomatic or pauci-symptomatic COVID-19 cases were not identified nor diagnosed and this fact caused a decrease in the effectiveness of the var...
Eligibility Criteria
Inclusion
- Elegibility to annual LDCT screening
- Absence of tumors for at least 5 years
- Signed informed consent form meet inclusion criteria outlined in SMILE Protocol NCT03654105
Exclusion
- Hypersensitivity to acetylsalicylic acid, salicylates or any of the excipients
- Chronic treatment with acetylsalicylic acid, or other anti-clotting or anti-coagulant drugs
- Treatment with methotrexate
- Existing Mastocytosis
- History of asthma induced by the administration of salicylates or substances to similar activity, particularly non-steroidal anti-inflammatory drugs
- Gastroduodenal ulcer
- Hemorrhagic diathesis
- Severe chronic pathology
- Serious psychiatric problems
- Previous treatment with Cytisine
- Abuse of alcohol or other substances
Key Trial Info
Start Date :
July 23 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
960 Patients enrolled
Trial Details
Trial ID
NCT04441814
Start Date
July 23 2019
End Date
December 1 2024
Last Update
March 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy, 20133